NIH-HL-20-814 NOSI (w links to R01 Clinical Trial and Clinical Trial Not Allowed) The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury

This NOSI seeks to support investigation into the factors and molecular mechanisms that address the heterogeneity dictated by the host resilience. Research on general host responses to injurious challenges and their effects on lung function as well as mechanisms that impact susceptibility to ARDS is not considered to be responsive to this announcement.

This NOSI encourages, but is not limited to, research applications in the following areas:

  • What are the host resilience factors (e.g., epigenetics, preexisting structural lung/heart/vascular or immune deficiencies, the severity of the lung inflammatory response) that influence resolution and recovery from ARDS/ALI?
  • What are the reparative or regenerative mechanisms that contribute to the resolution of lung injury and a return to a healthy host state?
  • What are the underlying host-response mechanisms that contribute to the disparity of resilience to ARDS/ALI in different race/ethnic groups and different age populations?
  • What are the underlying host-response mechanisms that determine the outcomes in patients with COVID-19 related ARDS?
  • What is the molecular mechanism underpinning the effect of metabolic changes and lifestyle on host resilience determining the resolution and recovery in ARDS?
  • Development of quantitative cell/organ/systems models and measures to identify resilience mechanisms involving inflammation resolution pathways in ARDS.

PA-20-183 - Research Project Grant (Parent R01 Clinical Trial Required)

PA-20-185 - Research Project Grant (Parent R01 Clinical Trial Not Allowed)

Sponsor or Type
Standard Dates through NOSI expiration on July 6, 2024

Subscribe to the UArizona Impact in Action newsletter to receive featured stories and event info to connect you with UArizona's research, innovation, entrepreneurial ventures, and societal impacts.

Subscribe now